Please note that assistive links (commonly known as "skip to links") are used throughout this site. These links are not well-supported by some mobile devices. If you are encountering difficulty using these links, please navigate around these links, or access the site on a desktop browser.
Skip to the primary content of this page Skip to the footer of this page
Provident Healthcare Partners Provident Healthcare Partners

Q2 2024 Pharmaceutical Commercialization Update

Provident Healthcare Partners
Skip to the end of the Expertise Menu

Q2 2024 Pharmaceutical Commercialization Update

M&A activity in the Pharma Commercialization services market demonstrated an uptick in transaction count in Q2 of 2024 as compared to the previous three quarters. The increase stems from continued add-on activity from the industry’s strategic acquirers and a sustained interest from private equity sponsors seeking a platform investment.

Provident expects M&A activity to remain strong throughout 2024 and beyond as companies continue to adopt data-driven strategies to enhance market access, optimize pricing, and personalize patient engagement. AI-powered platforms are also becoming increasingly important as they can be leveraged to create more efficient marketing and outreach strategies to both healthcare professionals and consumers. Additionally, the shift towards value-based care is influencing drug pricing and reimbursement models, requiring companies to further demonstrate clinical and economic benefits. As a result, both market research and market access firms are in high demand.

To print and download the full Pharmaceutical Commercialization Update report, please click below…

[holo_button icon=”/wp-content/uploads/2024/07/Q2-2024-Commercialization-vF.pdf”” color=”#003561″ target=”blank”]PRINT/DOWNLOAD[/holo_button]